Evidence map›Paper›PMID 34383785›Full record

ArticlePloS one2021

Cytomegalovirus infection in malignant pleural mesothelioma.

DeVon Hunter-Schlichting, Karl T Kelsey, Ryan Demmer, Manish Patel, Raphael Bueno, Brock Christensen, Naomi Fujioka, Deepa Kolarseri, Heather H Nelson

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Current management of CMV infection in cancer patients (solid tumors). Epidemiology and therapeutic strategies.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

DeVon Hunter-SchlichtingDivision of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, United States of America.ORCID 0000-0002-2986-9602
Karl T KelseyDepartment of Epidemiology and Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, United States of America.
Ryan DemmerDivision of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, United States of America.
Manish PatelDivision of Hematology and Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, United States of America.
Raphael BuenoDivision of Thoracic Surgery, Lung Center and International Mesothelioma Program, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America.ORCID 0000-0002-3231-5491
Brock ChristensenDepartment of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America.
Naomi FujiokaDivision of Hematology and Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, United States of America.
Deepa KolarseriMasonic Cancer Center University of Minnesota Twin Cities, Minneapolis, Minnesota, United States of America.
Heather H NelsonDivision of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, United States of America.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4M
Viral priming and targeting NK cells against solid tumor malignanciesR35CA197292 · NCI · UNIVERSITY OF MINNESOTA · PI MILLER, JEFFREY S. · 2015 to 2021
$6.2M
Validation of Prognostic and Diagnostic Molecular Tests in MesotheliomaR01CA120528 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUENO, RAPHAEL · 2006 to 2021
$4.8M
The Epidemiology of Molecular Alterations in MesotheliomaR01CA126939 · NCI · BROWN UNIVERSITY · PI KELSEY, KARL TIMOTHY · 2008 to 2012
$2.4M
NCI NIH HHS P30 CA077598NCI NIH HHS R01 CA120528NCI NIH HHS R01 CA126939NCI NIH HHS R35 CA197292
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) is a highly prevalent herpes virus which persists as a latent infection and has been detected in several different tumor types. HCMV disease is rare but may occur in high-risk settings, often manifesting as a pulmonary infection. To date HCMV has not been investigated in malignant pleural mesothelioma (MPM). In a consecutive case series of 144 MPM patients we evaluated two biomarkers of HCMV: IgG serostatus (defined as positive and negative) and DNAemia (>100 copies/mL of cell free HCMV DNA in serum). Approximately half of the MPM patient population was HCMV IgG seropositive (51%). HCMV DNAemia was highly prevalent (79%) in MPM and independent of IgG serostatus. DNAemia levels consistent with high level current infection (>1000 copies/mL serum) were present in 41% of patients. Neither IgG serostatus nor DNAemia were associated with patient survival. In tissues, we observed that HCMV DNA was present in 48% of tumors (n = 40) and only 29% of normal pleural tissue obtained from individuals without malignancy (n = 21). Our results suggest nearly half of MPM patients have a high level current HCMV infection at the time of treatment and that pleural tissue may be a reservoir for latent HCMV infection. These findings warrant further investigation to determine the full spectrum of pulmonary infections in MPM patients, and whether treatment for high level current HCMV infection may improve patient outcomes.

Indexed as

Mesothelioma, MalignantPleural NeoplasmsPneumonia, ViralAgedAntibodies, ViralCytomegalovirusCytomegalovirus InfectionsDisease-Free SurvivalDNA, ViralFemaleHumansImmunoglobulin GMaleMiddle AgedRetrospective StudiesSurvival RateAntibodies, ViralDNA, ViralImmunoglobulin G

Identifiers

PMID34383785
PMCPMC8360519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.